Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics Through Clinical Proof of ConceptAutoimmune Diseases, Biology, Biotech, Business, Drug Discovery, Fibrosis, Financing, Human Cells, Immuno-oncology, Integrins, Preclinical Data, Series B Preferred StockMorphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic. Read more September 25, 2018/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2018-09-25 07:30:512018-09-26 14:20:13Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics Through Clinical Proof of Concept
